Arjuna Capital’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.66M Buy
15,694
+7,396
+89% +$1.71M 0.82% 35
2026
Q2
$1.76M Sell
8,298
-31
-0.4% -$6.08K 0.4% 64
2026
Q1
$1.63M Sell
8,329
-1,134
-12% -$220K 0.42% 61
2025
Q4
$1.64M Buy
9,463
+328
+4% +$59.7K 0.4% 62
2025
Q3
$1.74M Buy
9,135
+491
+6% +$87.1K 0.43% 54
2025
Q2
$1.55M Sell
8,644
-687
-7% -$119K 0.41% 56
2025
Q1
$1.58M Sell
9,331
-783
-8% -$129K 0.44% 55
2024
Q4
$1.53M Sell
10,114
-14,800
-59% -$2.3M 0.41% 63
2024
Q3
$3.87M Buy
24,914
+23,128
+1,295% +$3.45M 1% 31
2024
Q2
$244K Buy
1,786
+16
+0.9% +$2.19K 0.07% 95
2024
Q1
$236K Buy
1,770
+88
+5% +$11.4K 0.07% 95
2023
Q4
$232K Sell
1,682
-11,381
-87% -$1.5M 0.07% 87
2023
Q3
$1.59M Buy
13,063
+478
+4% +$63.7K 0.57% 53
2023
Q2
$1.77M Buy
12,585
+645
+5% +$88.9K 0.63% 47
2023
Q1
$1.69M Buy
11,940
+9,337
+359% +$1.34M 0.66% 45
2022
Q4
$407K Buy
2,603
+95
+4% +$13.7K 0.19% 78
2022
Q3
$308K Buy
+2,508
New +$330K 0.15% 83

Other funds holding DGX

Arjuna Capital's DGX Position: Q3 2026 in Review

Arjuna Capital increased its Quest Diagnostics (DGX) stake by 89% in Q3 2026, buying an estimated $1.71M and bringing the position to 15,694 shares worth $3.66M. The position accounts for 0.82% of the portfolio, ranked #35.

Arjuna Capital first reported a position in DGX in Q3 2022 and has held it in 17 quarters since. The position peaked at $3.87M in Q3 2024. 722 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Arjuna Capital held 15,694 shares of Quest Diagnostics worth $3.66M as of Q3 2026.
  • Arjuna Capital bought 7,396 Quest Diagnostics shares in Q3 2026, an estimated $1.71M.
  • Quest Diagnostics made up 0.82% of Arjuna Capital's portfolio in Q3 2026, its #35 holding.
  • Arjuna Capital first reported a position in Quest Diagnostics in Q3 2022 and has held it in 17 quarters since.
  • Arjuna Capital's Quest Diagnostics position peaked at $3.87M in Q3 2024.
  • 722 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Arjuna Capital's 13F filing for Q3 2026, filed 3 Nov 2026.